Romiplostim Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Romiplostim Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Romiplostim Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxx6%
North Americaxxxxxxxxxxxx4.2%
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxx4.5%
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxx8%
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxx5.4%
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxx5.7%
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Romiplostim Market Type Segment Analysis According to Cognitive Market Research, 250 μg/0.5 Ml held the major market share over the forecast period Romiplostim dosing can be individualised with upto 10 mcg/kg1 as the maximum weekly dose. The starting dosage for is determined on the patient's actual weight. The subcutaneous injections of romiplostim once a week with adjusting the dose in accordance with the platelet count response are important factor. If achieving and maintaining a platelet count of at least 50 x 109/L is required to lower the risk of bleeding, use the lowest dose. When determining the dosage, the patient's actual body weight at the start of therapy should always be used. 500 μg/1 mL is the fastest-growing category over the forecast period. romiplostim provides a weekly subcutaneous injection in-office. There's no need to keep in mind to take a medication each day. There is no liver monitoring and no history of pharmacological interactions with statins, antacids, or antihypertensive drugs. No known dietary limitations (such as when administered with or without meals), therefore bread, milk, cereal, ice cream, cheese, and tofu are all acceptable. 250 μg/0.5 mL 500 μg/1 mL

250 μg/0.5 mL Romiplostim Market Analysis
XX
250 μg/0.5 mL Market Size 2025
XX %
CAGR
Locked · Full data in paid report
500 μg/1 mL Romiplostim Market Analysis
XX
500 μg/1 mL Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Romiplostim Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Romiplostim Industry News

In November 2012, Amgen announced that Nplate(TM) (romiplostim) is given marketing authorization in the European Union (EU) based on a positive judgement from the European Committee for Medicinal Products for Human Use (CHMP). For adults with splenectomized chronic immune thrombocytopenia purpura (ITP) who are not responding to alternative therapies, such as corticosteroids or immunoglobulins, the CHMP suggests Nplate. When surgery is not recommended, nplate may be used as a second line of treatment for adult non-splenectomized patients.

In October 2022, according to European Medicines Agenc, Nplate was proven to be beneficial for treating long-standing ITP in two major adult studies and a third study including children. In every study, Nplate was contrasted with a placebo, or fake treatment. The primary indicator of therapy efficacy for the patients, who had a 24-week course of treatment, was an increase in platelet count exceeding a threshold of 50 million platelets per millilitre of blood for at least six of the final eight weeks of treatment.

(Source: https://www.ema.europa.eu/en/medicines/human/EPAR/nplate)

In January 2024, Intas Pharmaceuticals, an Indian pharmaceutical company, received approval from the Central Drugs Standard Control Organization (CDSCO) for an additional pack of romiplostim injection (rDNA origin) 125 mcg/vial. This new presentation complements the existing 250 mcg and 500 mcg vial packs, providing more flexible dosing options for patients with chronic immune thrombocytopenia (ITP). Romiplostim is a thrombopoietin receptor agonist that stimulates platelet production, helping to reduce the risk of bleeding in ITP patients.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
AMGEN••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Romiplostim market size is USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 6.0% from 2024 to 2031. 

  • North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
  • Europe accounted for a share of over 30% of the global market size of USD XX million.
  • Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.
  • Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
  • Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Introduction of the Romiplostim Market 

An agonist of the thrombopoietin receptor, rimiplostim promotes platelet formation. In patients with persistent immune thrombocytopenic purpura (ITP), a bleeding disease brought on by a low platelet count, it is used to treat thrombocytopenia. Once a week, the medication is injected subcutaneously. The rising prevalence of ITP and other blood disorders is anticipated to propel the romiplostim market. For the treatment of thrombocytopenia in individuals with persistent immunological (idiopathic) thrombocytopenic purpura (ITP), the FDA has approved romiplostim, a thrombopoietin (TPO) receptor agonist. One glycoprotein that is crucial to the formation of platelets is TPO. When romiplostim binds to megakaryocytes' TPO receptor, platelet formation is stimulated. Leading industry participants are concentrating on and making investments in the romiplostim launch, which is expected to fuel market expansion during the projected time. Market participants are concentrating on lowering pharmaceutical costs so that patients afford to utilise the drug.

In July 2019, Romiplostim is introduced in India for the first time by intas, dramatically lowering the cost of Treating Chronic Immune Thrombocytopenia (ITP). The business that was the first to introduce Romiplostin also known as Romy in India is helping people with persistent immune thrombocytopenia (ITP) have easier access to treatment.

(Source: https://www.prnewswire.com/in/news-releases/intas-becomes-the-first-to-launch-romiplostim-in-india-significantly-reducing-the-treatment-cost-of-chronic-immune-thrombocytopenia-itp--852561451.html)

Analyst Conclusion

  • Author say's: The global romiplostim market will expand significantly by 6.0% CAGR between 2024 to 2031.
  • The adult segment is boosting the market growth due to the second or third line of treatment for primary immune thrombocytopenia (ITP), romiplostim is recommended for adults.
  • Romiplostim is recommended for paediatric patients who do not react to first-line treatment or who develop a steroid dependency due to its efficacy and safety features.
  • The hospital held the highest romiplostim market revenue share in 2024.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Romiplostim Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers AMGEN and others are profiled in the report.
Segments include Type, Application and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Romiplostim Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Type250 μg/0.5 mL, 500 μg/1 mL
ApplicationAdults, Pediatric Patients
End-UserHospitals, Clinics, Homecare
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies
List of CompetitorsAMGEN

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Romiplostim Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 AMGEN
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis

  • Chapter 2. Global Romiplostim Market Analysis

    • 2.1 Global Romiplostim Market Analysis
    • 2.2 Global Romiplostim Market Analysis by Region
    • 2.3 Global Romiplostim Market Analysis by Type
    • 2.4 Global Romiplostim Market Analysis by Application
    • 2.5 Global Romiplostim Market Analysis by End-User
    • 2.6 Global Romiplostim Market Analysis by Distribution Channel
    • 2.7 Global Romiplostim Market Analysis by Key Players

  • Chapter 3. North America Romiplostim Market Analysis

    • 3.1 North America Romiplostim Market Analysis
    • 3.2 North America Romiplostim Market Analysis by Country
    • 3.3 North America Romiplostim Market Analysis by Type
    • 3.4 North America Romiplostim Market Analysis by Application
    • 3.5 North America Romiplostim Market Analysis by End-User
    • 3.6 North America Romiplostim Market Analysis by Distribution Channel
    • 3.7 North America Romiplostim Market Analysis by Key Players

  • Chapter 4. Europe Romiplostim Market Analysis

    • 4.1 Europe Romiplostim Market Analysis
    • 4.2 Europe Romiplostim Market Analysis by Country
    • 4.3 Europe Romiplostim Market Analysis by Type
    • 4.4 Europe Romiplostim Market Analysis by Application
    • 4.5 Europe Romiplostim Market Analysis by End-User
    • 4.6 Europe Romiplostim Market Analysis by Distribution Channel
    • 4.7 Europe Romiplostim Market Analysis by Key Players

  • Chapter 5. Asia Pacific Romiplostim Market Analysis

    • 5.1 Asia Pacific Romiplostim Market Analysis
    • 5.2 Asia Pacific Romiplostim Market Analysis by Country
    • 5.3 Asia Pacific Romiplostim Market Analysis by Type
    • 5.4 Asia Pacific Romiplostim Market Analysis by Application
    • 5.5 Asia Pacific Romiplostim Market Analysis by End-User
    • 5.6 Asia Pacific Romiplostim Market Analysis by Distribution Channel
    • 5.7 Asia Pacific Romiplostim Market Analysis by Key Players

  • Chapter 6. South America Romiplostim Market Analysis

    • 6.1 South America Romiplostim Market Analysis
    • 6.2 South America Romiplostim Market Analysis by Country
    • 6.3 South America Romiplostim Market Analysis by Type
    • 6.4 South America Romiplostim Market Analysis by Application
    • 6.5 South America Romiplostim Market Analysis by End-User
    • 6.6 South America Romiplostim Market Analysis by Distribution Channel
    • 6.7 South America Romiplostim Market Analysis by Key Players

  • Chapter 7. Middle East Romiplostim Market Analysis

    • 7.1 Middle East Romiplostim Market Analysis
    • 7.2 Middle East Romiplostim Market Analysis by Country
    • 7.3 Middle East Romiplostim Market Analysis by Type
    • 7.4 Middle East Romiplostim Market Analysis by Application
    • 7.5 Middle East Romiplostim Market Analysis by End-User
    • 7.6 Middle East Romiplostim Market Analysis by Distribution Channel
    • 7.7 Middle East Romiplostim Market Analysis by Key Players

  • Chapter 8. Africa Romiplostim Market Analysis

    • 8.1 Africa Romiplostim Market Analysis
    • 8.2 Africa Romiplostim Market Analysis by Country
    • 8.3 Africa Romiplostim Market Analysis by Type
    • 8.4 Africa Romiplostim Market Analysis by Application
    • 8.5 Africa Romiplostim Market Analysis by End-User
    • 8.6 Africa Romiplostim Market Analysis by Distribution Channel
    • 8.7 Africa Romiplostim Market Analysis by Key Players

  • Chapter 9. Type Analysis

    • 9.1 250 μg/0.5 mL
      • 9.1.1 Global 250 μg/0.5 mL Market
      • 9.1.2 Global 250 μg/0.5 mL Market by Region
    • 9.2 500 μg/1 mL
      • 9.2.1 Global 500 μg/1 mL Market
      • 9.2.2 Global 500 μg/1 mL Market by Region

  • Chapter 10. Application Analysis

    • 10.1 Adults
      • 10.1.1 Global Adults Market
      • 10.1.2 Global Adults Market by Region
    • 10.2 Pediatric Patients
      • 10.2.1 Global Pediatric Patients Market
      • 10.2.2 Global Pediatric Patients Market by Region

  • Chapter 11. End-User Analysis

    • 11.1 Hospitals
      • 11.1.1 Global Hospitals Market
      • 11.1.2 Global Hospitals Market by Region
    • 11.2 Clinics
      • 11.2.1 Global Clinics Market
      • 11.2.2 Global Clinics Market by Region
    • 11.3 Homecare
      • 11.3.1 Global Homecare Market
      • 11.3.2 Global Homecare Market by Region

  • Chapter 12. Distribution Channel Analysis

    • 12.1 Hospital Pharmacies
      • 12.1.1 Global Hospital Pharmacies Market
      • 12.1.2 Global Hospital Pharmacies Market by Region
    • 12.2 Retail Pharmacies
      • 12.2.1 Global Retail Pharmacies Market
      • 12.2.2 Global Retail Pharmacies Market by Region
    • 12.3 Online Pharmacies
      • 12.3.1 Global Online Pharmacies Market
      • 12.3.2 Global Online Pharmacies Market by Region

  • Chapter 13. Qualitative Analysis (Subject to Data Availability)

    • 13.1 Market Drivers
    • 13.2 Market Restraints
    • 13.3 Market Trends
    • 13.4 Market Opportunity
    • 13.5 Technological Road Map (Subject to Data Availability)
    • 13.6 Product Life Cycle (Subject to Data Availability)
    • 13.7 Customer and Buyer Behavior Analysis
      • 13.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 13.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 13.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 13.7.4 Pricing, Affordability & Value Perception Analysis
      • 13.7.5 Customer Segmentation & Demand Pattern Analysis
    • 13.8 PESTEL Analysis
      • 13.8.1 Political Factors
      • 13.8.2 Economic Factors
      • 13.8.3 Social Factors
      • 13.8.4 Technological Factors
      • 13.8.5 Legal Factors
      • 13.8.6 Environmental Factors
    • 13.9 Industrial Chain Analysis (Subject to Data Availability)
      • 13.9.1 Industry Chain Analysis
      • 13.9.2 Manufacturing Cost Analysis
      • 13.9.3 Supply Side Analysis
        • 13.9.3.1 Raw Material Analysis
        • 13.9.3.2 Raw Material Procurement Analysis
        • 13.9.3.3 Raw Material Price Trend Analysis
    • 13.10 Porter’s Five Forces Analysis
      • 13.10.1 Bargaining Power of Suppliers
      • 13.10.2 Bargaining Power of Buyers
      • 13.10.3 Threat of New Entrants
      • 13.10.4 Threat of Substitutes
      • 13.10.5 Degree of Competition
    • 13.11 Patent Analysis (Subject to Data Availability)
    • 13.12 ESG Analysis
    • 13.13 Geopolitical Outlook
      • 13.13.1 Global Power Realignment & Strategic Alliances
      • 13.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 13.13.3 International Trade Relations & Market Access Environment
      • 13.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 13.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 13.13.6 Technology Sovereignty & Digital Geopolitics
      • 13.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 13.14 AI & Market Transformation
      • 13.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 13.14.2 AI-Driven Transformation of Industry Value Chain
      • 13.14.3 Evolution of Business Models & Revenue Streams
      • 13.14.4 AI-Driven Product, Service & Innovation Transformation
      • 13.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 14. TOP 10 Country Analysis

    • 14.1 Country 1
    • 14.2 Country 2
    • 14.3 Country 3
    • 14.4 Country 4
    • 14.5 Country 5
    • 14.6 Country 6
    • 14.7 Country 7
    • 14.8 Country 8
    • 14.9 Country 9
    • 14.10 Country 10

  • Chapter 15. Research Findings

    • 15.1 Key Takeaways
    • 15.2 Analyst Point of View
    • 15.3 Assumptions and Acronyms

  • Chapter 16. Research Methodology and Sources

    • 16.1 Primary Data Collection
      • 16.1.1 Steps for Primary Data Collection
        • 16.1.1.1 Identification of KOL
      • 16.1.2 Backward Integration
      • 16.1.3 Forward Integration
      • 16.1.4 How Primary Research Help Us
      • 16.1.5 Modes of Primary Research
    • 16.2 Secondary Research
      • 16.2.1 How Secondary Research Help Us
      • 16.2.2 Sources of Secondary Research
    • 16.3 Data Validation
      • 16.3.1 Data Triangulation
    • 16.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Romiplostim Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 1+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Romiplostim Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the romiplostim market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.